IQVIA (IQV) investor relations material

AI strategy and implementation

• AI is viewed as a strong net positive, driving efficiency and incremental revenue across clinical and commercial operations.

• Proprietary, dynamic, and highly curated data forms a significant competitive moat, with 70% of pharma data sourced internally.

• Over 150 AI agents have been deployed in workflows, with more than 90 AI patents filed, enhancing processes like protocol design and patient enrollment.

• AI tools such as the IQVIA AI Assistant and DaaS+ enable rapid product launch simulations and seamless data integration for clients.

• AI-driven efficiencies are monetized as incremental offerings, not as price competition, and are expected to replace some traditional analytics revenue over time.

Market dynamics and demand outlook

• Post-COVID and regulatory changes led to volatility, but the environment has stabilized, with client confidence and funding returning.

• Biotech remains a key growth driver, with high single-digit R&D investment growth and dedicated resources to improve win rates.

• Large pharma partnerships remain strong, with a shift back from FSP models as outsourcing becomes more economically viable.

• Bookings and backlog growth are emphasized over short-term metrics like book-to-bill due to the long-cycle nature of the business.

Strategic initiatives and acquisitions

• Recent acquisition of Cedar Gate expands capabilities in the US payer-provider space, enhancing patient analytics and real-world evidence offerings.

• Cedar Gate brings $140 million in revenue, strong margins, and synergies with existing patient data and claims analytics.

• Investments in biotech funds provide early access to innovative assets and support growth in the biotech segment.

• Dedicated organizational structures and resources have been established to support both biotech and large pharma clients.